

Seeking Vaccine Candidates with Cross-protection Against Canine Leptospira

Our client is seeking **novel vaccine candidates to protect against canine leptospirosis** and/or leptospiuria. They aim to improve on the currently available vaccines, particularly those with immunity to one specific serovar, typically from inactivated bacteria.

Novel vaccines should provide **cross-protection against multiple leptospira serovar** from the following list: *Leptospira pomona*; *L. canicola*; *L. icterohaemorrhagiae*; *L. grippotyphosa*; *L. bratislava*; *L. australis*; *L. copenhageni* and *L. autumnalis*.



Approaches of Interest:

- The vaccine candidate should provide cross protection against at least two of the serovars listed, however more comprehensive protection is desirable
- Our client is open to vaccine formulations that provide cross-protection, and could comprise:
 - A recombinant or chimeric proteins (subunit), or multiple proteins that provide cross-protection in combination
 - Vectored vaccines
 - Modified-live vaccines

Out of Scope:

- Killed (inactivated) vaccines.
- Leptospira vaccine development in non-canine species, unless readily applicable to achieve protection in canines.

Developmental Stages of Interest:

- Cross-protection should be demonstrated in hamster challenge model, or an equivalent small animal model.
- Validation in a canine model is desirable.

Submission Information

Submission of one-page, 200–300-word briefs is required, along with any relevant supplementary information e.g. relevant publications, patents. **You are encouraged to outline the validation achieved for your technology, and next steps towards commercialisation.** This campaign is open to submissions from academia and industry, including start-ups. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client has commercial funding available for a collaboration, with necessary resources to progress suitable technologies from research through commercial development. Any such collaboration (including funding amount, timeline etc.) will be discussed on a case-by-case basis with selected submissions. Licensing of technologies and associated IP will also be considered.

Opportunities sought

-  Technologies
-  Biotech assets
-  Research projects

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **30th March 2026 - 10:59 pm GMT**

Have any questions?

Contact our team at campaigns@inpart.io